Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma
Status:
Completed
Trial end date:
2010-05-01
Target enrollment:
Participant gender:
Summary
This phase II trial is studying the side effects of giving erlotinib together with
carboplatin and paclitaxel and to see how well it works in treating patients with stage III
or stage IV ovarian, fallopian tube, or primary peritoneal cancer. Biological therapies such
as erlotinib may interfere with the growth of tumor cells and slow the growth of the tumor.
Drugs used in chemotherapy such as carboplatin and paclitaxel use different ways to stop
tumor cells from dividing so they stop growing or die.